Ignite Creation Date:
2024-05-06 @ 1:39 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01869816
Status:
COMPLETED
Last Update Posted:
2020-09-02
First Post:
2013-06-02
Brief Title:
CTRP3 and Progranulin in Patients With Coronary Artery Disease
Sponsor:
Korea University
Organization:
Korea University
Study Overview
Official Title:
Implications of C1qTNF-related Protein-3CTRP-3 and Progranulin in Patients With Acutecoronary Syndrome and Stable Angina Pectoris
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease CVD Progranulin and CTRP3 are recently discovered novel adipokines Therefore the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors
Detailed Description:
CTRP-3 synonyms CORS-26 cartducin and cartonectin is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes Using a recently developed enzymelinked immunosorbent assay ELISA we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation
Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 IL-6 in adipose tissue We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue Moreover the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease CAD In the present study we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors
Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 IL-6 in adipose tissue We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue Moreover the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease CAD In the present study we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None